ASX ANNOUNCEMENT **21 October 2024**

$5 million Placement to progress CHM CDH17 through Phase 1/2 trial

- **Capital raising was supported by a range of institutional, professional and sophisticated investors**
- **Funds will be used primarily to advance the CHM CDH17 CAR-T program through the recently commenced Phase 1/2 clinical trial**
- **Executive Chairman Paul Hopper to participate with $1 million investment**

Sydney, Australia, 21 October 2024: Chimeric Therapeutics (ASX:CHM, "Chimeric" or the "Company"), an Australian leader in cell therapy, advises it has received commitments for a capital raising of $5 million before costs by way of a two-tranche placement to sophisticated and professional investors (**Placement Subscribers**) at an issue price of $0.008 (0.8 cents) per new fully paid ordinary share (**Placement Share**), with the issue of tranche two Placement Shares and any Placement Shares to be issued to Directors subject to shareholder approval (**Placement**).

The Placement will raise approximately $5 million before costs via a two-tranche issue of approximately 625 million new fully paid Placement Shares at $0.008 per Placement Share (**Offer Price**) together with 1 unlisted option (with an exercise price of $0.008, expiring 12 months from the grant date) (**Placement Option**) for every 1 Placement Share issued, and is subject to CHM shareholder approval as below.

Chimeric's Executive Chairman, Mr Paul Hopper, has committed to subscribe for 125 million Placement Shares (representing $1 million of the $5 million Placement) to be issued to him or his nominee, subject to shareholder approval.

The Offer Price for the Placement Shares represents a:

- 42.9% discount to the last closing price of $0.014 on 30 September 2024 (being the last day of trading of CHM shares prior to this announcement); and
- 45.6% discount to the 15-day VWAP (volume weighted average price) on 30 September 2024.

Under the Placement, approximately 69.99 million Placement Shares will be issued under the Company's capacity under ASX Listing Rule 7.1. The remaining approximately 555 million Placement Shares (including the 125 million Placement Shares to be subscribed for by Mr Hopper) plus the 625 million Placement Options will be issued subject to shareholder approval at an extraordinary general meeting (**Meeting**). The Company will convene a Meeting as soon as practical (anticipated to be held in December 2024) to seek shareholder approval. Should shareholders not approve the issue of the 555 million Placement Shares (including Mr Hopper's

Placement Shares) and the Placement Options there is no penalty or other payment to be incurred by the Company, however, the Company will not receive the remaining funds committed by Placement Subscribers or Mr Hopper.

Allotment and issue of the 69.99 million Placement Shares under the Company's existing Listing Rule 7.1 capacity is expected to occur on Wednesday 23 October 2024, with normal trading of these Placement Shares expected to commence on Thursday 24 October 2024.

PAC Partners Securities Pty Ltd and Taylor Collison Limited acted as Joint Lead Manager to the Placement and, as part of their mandate, will be issued with 55 million unlisted options with an exercise price of $0.016 ea. and expiring 3 years from issue date (subject to shareholder approval).

Use of funds

Proceeds from the Placement will be used primarily to support the clinical trial pipeline and therapy portfolio, including:

- CHM CDH17 CAR-T Program: CHM has dosed the first patient in this Phase 1/2 trial in patients with neuroendocrine tumours, colorectal cancer and gastric cancer. With two clinical trial sites now active and enrolling; Sarah Cannon Cancer Centre in Nashville Tennessee and UPenn in Philadelphia, PA. GMP Manufacturing has been established with a successful first patient run. More sites are scheduled to be opened in H2 2024; with the aim to enroll up to 15 patients by the end of FY25.
- CHM CLTX Program: CHM CLTX is a novel CAR T Therapy currently in Phase 1b clinical trial in recurrent and/or progressive glioblastoma multiforme (GBM – Brain Cancer). Initial positive data from the investigator-initiated trial has been presented.
- CORE NK Platform: Building off the success in the phase 1A clinical trial where one patient achieved a complete response that has been sustained now for over 48 months, CHM in partnership with Case Western University has commence a novel Phase 1B clinical trial with our CORE NK platform. The trial is the first-ever trial to assess NK cells in combination with Vactosertib in patients with advanced colorectal and blood cancers; one patient in this trial with AML has also achieved a complete response with no evidence of cancer at day 28.
  In addition, CHM in partnership with MD Anderson Cancer Centre have commenced a trial to evaluate the synergy of NK cell therapy in combination with the current standard of care for blood cancer, Azacitidine and Venetoclax (aza/ven). Both trials are supported by our partner institutions.
- General working capital and costs of the capital raising.

ABOUT CHIMERIC THERAPEUTICS

Chimeric Therapeutics, a clinical stage cell therapy company and an Australian leader in cell

therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer. To bring that promise to life for more patients, Chimeric's world class team of cell therapy pioneers and experts is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies.

Chimeric currently has a diversified portfolio that includes first in class autologous CAR T cell therapies and best in class allogeneic NK cell therapies. Chimeric assets are being developed across multiple different disease areas in oncology with 3 clinical stage programs.

CHM CDH17 is a first-in-class, 3rd generation CDH17 CAR T invented at the world-renowned cell therapy centre, the University of Pennsylvania (Penn) in the laboratory of Dr. Xianxin Hua, professor in the Department of Cancer Biology in the Abramson Family Cancer Research Institute at Penn. Preclinical evidence for CDH17 CAR T was published by Dr. Hua and his colleagues in March 2022 in Nature Cancer demonstrating complete eradication of tumours in 7 types of cancer in mice. CHM CDH17 is currently being studied in a phase 1/2 clinical trial in gastrointestinal and neuroendocrine tumours that was initiated in 2024.

CHM CLTX is a novel and promising CAR T therapy developed for the treatment of patients with solid tumours. CLTX CAR T is currently being studied in a phase 1B clinical trial in recurrent / progressive glioblastoma. Positive preliminary data from the investigator-initiated phase 1A trial in glioblastoma was announced in October 2023.

CHM CORE-NK is a potentially best-in-class, clinically validated NK cell platform. Data from the complete phase 1A clinical trial was published in March 2022, demonstrating safety and efficacy in blood cancers and solid tumours. Based on the promising activity signal demonstrated in that trial, two additional Phase 1B clinical trials investigating CORE-NK in combination regimens have been initiated. From the CORE-NK platform, Chimeric has initiated development of new next generation NK and CAR NK assets.

Authorised on behalf of the Chimeric Therapeutics board of directors by Chairman Paul Hopper.

CONTACT

Investors
Dr Rebecca McQualter
Chief Operating Officer
Chimeric Therapeutics
T: +61 498 966 180
E: investors@chimerictherapeutics.com
W: www.chimerictherapeutics.com

Media
Matthew Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au